Teva Pharmaceuticals USA Inc recalls Azacitidine for Injection 100mg/vial Lyophilized Powder
The stated reason: Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay.
Teva Pharmaceuticals USA Inc began a drug recall on July 22, 2022 whose reported distribution included Ohio. FDA
What the record shows
in Romania By: Sindan Pharma SRL For BluePoint Laboratories, NDC 68001-313-56 beginning July 22, 2022, in a drug recall whose distribution included Ohio. Results below specification. FDA graded it Class III — use is not likely to cause adverse health consequences. Quantity affected: 4162 cartons. The recall is listed as terminated. FDA
Context
By the numbers
- Date of record: July 22, 2022 FDA
- Recall number: D-1334-2022 FDA
- Recalls in this action: 1 FDA
- Recalling firm: Teva Pharmaceuticals USA Inc FDA
- Product: Azacitidine for Injection 100mg/vial Lyophilized Powder, Rx Only, Mfd. in Romania By: Sindan Pharma SRL For BluePoint… FDA
- Reason for recall: Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below… FDA
Assembled mechanically from the source filing and The Lantern's own record database — no AI-written prose. Every figure above appears verbatim in the cited record, which is linked on this page. FDA
Sources
The source filing
| Recall number | D-1334-2022 |
|---|---|
| Recalls in this action | 1 |
| Recalling firm | Teva Pharmaceuticals USA Inc |
| Product | Azacitidine for Injection 100mg/vial Lyophilized Powder, Rx Only, Mfd. in Romania By: Sindan Pharma SRL For BluePoint Laboratories, NDC 68001-313-56 |
| Reason for recall | Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below specification. |
| Classification | Class III — use is not likely to cause adverse health consequences |
| Recall type | drug |
| Quantity | 4162 cartons |
| Status | Terminated |
| Voluntary or mandated | Voluntary: Firm initiated |
| Initiated | 20220722 |
| Reported | 20220817 |
| Distribution | Distributed in Ohio |
| Firm location | Parsippany, NJ, United States |
Published by U.S. Food and Drug Administration (openFDA). This is the agency's public filing as The Lantern received it, shown with its fields named in plain English.